Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B2NV
|
|||
| Drug Name |
PMID29334795-Compound-22
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Patented | [1] | |
| Neuropathic pain [ICD-11: 8E43.0] | Patented | [1] | ||
| Company |
LES LABORATOIRES SERVIELES LABORATOIRES SERVIER ROBERT, Nicolas LERESTIF, Jean-Michel LECOUVE, Jean-Pierre GAILLARD, Marina DELCROIX - MEUNIER, Julie LETELLIER, Philippe BOIRET, MathieLES LABORATOIRES SERVIER TROCME-THIBIERGE, Caryn SORS, Aurore KEIME GUIBERT, FlorencLES LABORATOIRES SERVIER CASARA, Patrick CHOLLET, Anne-Marie DHAINAUT, Alain BERT, Lionel LESTAGE, Pierre LOCKHART, Brian
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H3 receptor (H3R) | Target Info | Agonis; Inverse agonist | [1] |
| Target's Patent Info | Histamine H3 receptor (H3R) | Target's Patent Info | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Histamine receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Monoamine Transport | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.